Sign in
Taking people in United StatesPhase 2

Atorvastatin added to a beta blocker in advanced cirrhosis of the liver

Tests atorvastatin plus a beta blocker in adults with decompensated cirrhosis.

Key facts

Who runs it
CAMC Health System
Where
Charleston, United StatesSee the site
Trial code
Registry title
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
9 Sept 2025
Expected to end
Mar 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Atorvastatin 20 mg
  • Placebo
Record updated
25 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with decompensated cirrhosis (advanced liver scarring with serious problems) who already take a non-selective beta-blocker. It compares atorvastatin with placebo, both added to the beta-blocker.

Age
18 years or older
Sex
All sexes
Disease stage
Decompensated liver disease: fluid buildup in the belly (ascites), confusion from liver disease (hepatic encephalopathy), or bleeding from swollen veins (variceal bleed). Patients must come to CAMC Memorial Hospital or the CAMC-Gastroenterology Liver Clinic.
Earlier treatment
Must currently take a non-selective beta-blocker. Cannot be taking a statin now. Must agree to liver care at the CAMC-Gastroenterology Liver Clinic for 12 months.

Main reasons for not taking part

  • Liver cancer (hepatocellular carcinoma)
  • Ongoing alcohol use, more than one drink per week
  • IV drug use or a history of not taking medicines as told
  • Past statin intolerance, or taking medicines that interact with statins
  • On the waitlist for a liver transplant

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients age of 18 years or older diagnosed with any form of decompensated liver disease defined as ascites, hepatic encephalopathy, or variceal bleed presenting at Charleston Area Medical Center (CAMC) Memorial Hospital or CAMC-Gastroenterology Liver Clinic
  • Currently on an non-selective beta-blockers agreeing to have their liver disease managed by CAMC-Gastroenterology Liver Clinic as an outpatient for the 12-month follow-up period

Who cannot take part

  • Patients currently on statin therapy
  • Patients on the waitlist for liver transplantation
  • Patients taking medications with known drug interactions with statins
  • Patients exhibiting high-risk behaviors that could put them at risk for complications including IV substance use and history of medication non-adherence
  • Patients with a history of statin intolerance
  • Any patient <18 years of age
  • Patients with hepatocellular carcinoma
  • Patients with ongoing alcohol use (self-reported consumption of more than one alcoholic drink per week)
  • Patients not able to give informed consent or patients belonging to vulnerable categories as the Federal Regulations or Common Rule

Where in United States

  • Charleston Area Medical CenterCharleston, United StatesContact: Nadeem Anwar, MDTaking people

About the trial

What the trial wants to find out

Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion. This reduced decreased liver function subsequently decreases life expectancy. There is a critical need for strategies to delay progression to decompensation and reduce the occurrence of serious complications. Currently, limited therapeutic options are available for managing decompensated liver disease, with beta-blockers (BB) being the only proven medication with significant benefits in preventing disease progression. Statins have been historically under- prescribed in cirrhosis due to concerns of liver damage. However, there is emerging evidence that statin use may be beneficial and able to lessen liver disease worsening, with studies demonstrating its safety. Thus, we aim to conduct a pilot randomized controlled trial (RCT) study of 50 subjects comparing the outcomes of decompensated cirrhotic patients receiving the statin, atorvastatin, and a non-selective beta-blocker (NSBB) versus those receiving NSBB plus placebo. Both groups will be followed for 12 months to investigate the feasibility, safety, and efficacy of combination therapy.

The 2 groups in the trial

  • NSBB plus statinExisting treatment, for comparison

    Atorvastatin 20 mg once daily along with previously prescribed NSBB

    Treatment: Atorvastatin 20 mg

  • NSBB plus placeboPlacebo, for comparison

    Placebo once daily along with previously prescribed NSBB

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study of Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
Plain-language title
Atorvastatin added to a beta blocker in advanced cirrhosis of the liverGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
25 February 2026